This 45-minute Roundtable will explore how using combination strategies in aging biology is creating new therapeutic leverage. Aging is multifactorial, and single agents often hit only one hallmark; combinations (small molecules, biologics, senolytics + immunomodulators, etc.) offer synergy, but also complexity. The discussion will focus on how to rationally design, validate, and translate combination regimens in aging and age-related disease fields.

• Exploring synergies between senotherapeutics, metabolic modulators, and immunetargeted agents
• Repurposing existing drugs alongside novel therapies to boost impact
• Rethinking dosing, timing, and safety frameworks for older populations
• Defining translational and regulatory pathways for combination therapies in aging